Drugs / Vepoliximab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07677813 Background | Jun 2026 → Dec 2029 expected | MCD diffuse large B-cell lymphoma | Ou Bai, MD/PHD | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vepoliximab | “Vepoliximab: 1.8 mg/kg, Day 1” NCT07677813 ↗ |